6533b7d2fe1ef96bd125f774

RESEARCH PRODUCT

Adult congenital heart disease: Special considerations for COVID-19 and vaccine allocation/prioritization

Pier Paolo BassareoMichael A. GatzoulisIlaria CazzoliJ SabatinoJ SabatinoGiovanni Di SalvoGiuseppe CalcaterraPaolo GuccioneMaria Pia CalabròLilia Oreto

subject

Prioritizationmedicine.medical_specialtyHeart diseaseCoronavirus disease 2019 (COVID-19)business.industryAdverse outcomesCOVID-19medicine.diseaseRisk profileArticleRisk factorsSchema (psychology)RC666-701ACHDMedicineDiseases of the circulatory (Cardiovascular) systembusinessIntensive care medicineClinical risk factorVaccine

description

Abstract Individuals with the highest risk for adverse outcomes of COVID-19 should be prioritized by the vaccine allocation policies. We have conducted a literature review of published studies, which comprehend congenital heart disease (CHD) and COVID-19, in order to present the overall evidences of both exposure and clinical risk of patients with adult congenital heart disease (ACHD) and to propose a risk profile schema for those patients to be incorporated into vaccine distribution decisions.

yearjournalcountryeditionlanguage
2021-08-01
10.1016/j.ijcchd.2021.100186http://hdl.handle.net/11577/3402526